5-Aza-2'-deoxycytidine (Decitabine),DNMT1抑制剂(ab120842)
Key features and details
- Potent DNMT1 inhibitor. Induces DNA hypomethylation.
- CAS Number: 2353-33-5
- Purity: > 99%
- Soluble in water to 50 mM and in DMSO to 50 mM
- Form / State: Solid
- Source: Synthetic
概述
-
产品名称
5-Aza-2'-deoxycytidine (Decitabine),DNMT1抑制剂 -
描述
Potent DNMT1抑制剂. Induces DNA hypomethylation. -
别名
- 5-AzadCyD
- Dacogen
- Decitabine
- NSC 127716
-
生物学描述
Potent DNA methyltransferase 1 (DNMT1) inhibitor (IC50 = 0.2 μM). Incorporated into DNA, inhibits DNMT1 activity to induce DNA hypomethylation. Interferes with protein synthesis. Shows antimetabolic and anticancer activities in vitro. Active in vivo.
-
纯度
> 99% -
CAS编号
2353-33-5 -
化学结构
性能
-
化学名称
4-Amino-1-(2-deoxy-β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one -
分子量
228.21 -
分子式
C8H12N4O4 -
PubChem识别号
451668 -
存放说明
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解度概述
Soluble in water to 50 mM and in DMSO to 50 mM -
处理
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O -
来源
Synthetic
-
研究领域
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
文献 (9)
ab120842 被引用在 9 文献中.
- Ralser DJ et al. ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade. Biomark Res 11:56 (2023). PubMed: 37259155
- Kim JY et al. Time-resolved proteomic analyses of senescence highlight metabolic rewiring of mitochondria. Life Sci Alliance 6:N/A (2023). PubMed: 37321846
- Hoffmann F et al. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma. Clin Epigenetics 15:112 (2023). PubMed: 37415208
- Niebel D et al. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. Clin Epigenetics 14:50 (2022). PubMed: 35410311
- Li J et al. SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis. Br J Cancer 125:865-876 (2021). PubMed: 34274945
- Moujalled DM et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 33:905-917 (2019). PubMed: 30214012
- Evans MR et al. Human Papillomavirus 16 E2 Regulates Keratinocyte Gene Expression Relevant to Cancer and the Viral Life Cycle. J Virol 93:N/A (2019). PubMed: 30518656
- Mulati K et al. VISTA expressed in tumour cells regulates T cell function. Br J Cancer 120:115-127 (2019). PubMed: 30382166
- Zeng X et al. Secreted Frizzled Related Protein 2 Modulates Epithelial-Mesenchymal Transition and Stemness via Wnt/ß-Catenin Signaling in Choriocarcinoma. Cell Physiol Biochem 50:1815-1831 (2018). PubMed: 30396168